Loading
Nanoplatforms for Cancer Theranostics / Cancer Research and Treatments · Journal article
Frontiers in Immunology · July 30, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing mechanistic understanding of the CD73-adenosine axis in melanoma immunosuppression and exploring therapeutic strategies to target this pathway in combination with checkpoint inhibitors. The work is conceptual and raises questions about clinical utility of CD73 as a biomarker and the therapeutic potential of adenosinergic blockade, but does not present primary evidence, clinical trial results, or outcome data to support practice recommendations.
Narrative review. Melanoma (advanced, ICI-resistant).
CD73-adenosine axis functions as a metabolic immune checkpoint orchestrating immunosuppressive tumor microenvironment in melanoma. CD73 expression is regulated by convergent mechanisms including hypoxia-stabilized HIF-1α, MAPK signaling, TGF-β, and TNF-α. CD73 has dichotomous significance when expressed on tumor versus immune cells as a prognostic and predictive biomarker.
Liquid biopsy monitoring strategies and CRISPR/Cas9 approaches discussed as future directions without clinical validation or safety data.
This review contextualizes CD73-adenosine blockade as a potential strategy to overcome ICI resistance in melanoma, but clinicians should recognize that the evidence presented is mechanistic and translational; no clinical trial results or outcome comparisons are reported to guide immediate practice decisions.
This is a narrative review that synthesizes mechanistic evidence and emerging therapeutic concepts without reporting primary trial data, clinical outcomes, or comparative effectiveness.
As stated by the source record.
This review contextualizes CD73-adenosine blockade as a potential strategy to overcome ICI resistance in melanoma, but clinicians should recognize that the evidence presented is mechanistic and translational; no clinical trial results or outcome comparisons are reported to guide immediate practice decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The therapeutic landscape of advanced melanoma has been transformed by immune checkpoint inhibitors (ICIs); however, primary and acquired resistance remain formidable challenges for a substantial subset of patients. Emerging evidence identifies the CD73-adenosine axis as a critical “metabolic immune checkpoint” that orchestrates an immunosuppressive tumor microenvironment (TME). This review systematically explores the biochemical cascade in which extracellular ATP is converted into immunosuppressive adenosine by the sequential action of ectonucleotidases CD39 and CD73. We detail the multidimensional regulation of CD73 expression, driven by a convergence of environmental stressors such as hypoxia-stabilized HIF-1α, oncogenic MAPK signaling, and pro-inflammatory cytokines including TGF-β and TNF-α. Furthermore, we evaluate the clinical utility of CD73 as a prognostic and predictive biomarker, highlighting the dichotomous significance of its expression on tumor versus immune cells and the potential of liquid biopsy-based monitoring via soluble CD73 activity and melanoma-derived exosomes (MTEX). Finally, we discuss therapeutic strategies to dismantle this metabolic barrier, ranging from monoclonal antibodies and small-molecule inhibitors to synergistic combinations with ICIs, targeted therapies, and next-generation cellular engineering utilizing CRISPR/Cas9-mediated gene editing. Integrating adenosinergic blockade into the framework of precision immuno-oncology represents a pivotal dimension in overcoming treatment resistance and improving clinical outcomes for patients with melanoma.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.